Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : Recent Findings from Johnson & Johnson Provides New Insights into Silicic Acid (Waterborne layered silicate/acrylate nanocomposites by in-situ...

share with twitter share with LinkedIn share with facebook
share via e-mail
12/08/2016 | 09:59pm CET

Recent Findings from Johnson & Johnson Provides New Insights into Silicic Acid (Waterborne layered silicate/acrylate nanocomposites by in-situ emulsion polymerization: Thermal and mechanical reinforcement)

By a News Reporter-Staff News Editor at Life Science Weekly -- Current study results on Silicic Acid have been published. According to news reporting out of Jacksonville, Florida, by NewsRx editors, research stated, "Layered silicate acrylateibentonite nanocomposites were synthesized by seeded batch emulsion polymerization. The acrylates were based on butyl acrylate (BA), methyl methacrylate (MMA), and acrylic acid (AA) with composition 56:42:2."

Financial support for this research came from Mexican Council for Science and Technology (see also Silicic Acid).

Our news journalists obtained a quote from the research from Johnson & Johnson, "Surface untreated nanoclay, bentonite, was incorporated in situ up to 3 wt%. Coating films obtained from the aqueous dispersions were optically transparent. Transmission and scanning electron microscopy (TEM, SEM) showed that bentonite was aggregated into clusters dispersed throughout the polymer matrix, and TEM and wide-angle X-ray scattering (WAXS) confirmed that the silicate layers were intercalated by the macromolecules. The nanocomposites exhibited higher onset for thermal degradation temperature, T-onset, and higher glass transition temperature, T-g, increasing up to 20 degrees C and 6 degrees C, respectively, relative to the neat acrylate. Strikingly, the dynamic elastic modulus E' increased over two orders of magnitude at only 3 wt% concentration of bentonite. Furthermore, the et relaxation, denoted by maximum tan 8 (=E'/E') was shifted to higher temperatures and its strength significantly attenuated thus reflecting a decrease in toughening, and evidencing the slowdown of long range molecular motions associated to the glass transition. The mechanical reinforcement was confirmed by uniaxial tensile tests, the Youngis modulus E exhibited a 5-fold increase at only 1 wt% bentonite content."

According to the news editors, the research concluded: "The modification of long range molecular motions evidenced by dynamic mechanical analysis would be associated to the restricted motions of the macromolecules confined within the clay nanoplatelets."

For more information on this research see: Waterborne layered silicate/acrylate nanocomposites by in-situ emulsion polymerization: Thermal and mechanical reinforcement. Progress in Organic Coatings, 2016;101():59-70. Progress in Organic Coatings can be contacted at: Elsevier Science Sa, PO Box 564, 1001 Lausanne, Switzerland. (Elsevier - www.elsevier.com; Progress in Organic Coatings - www.journals.elsevier.com/progress-in-organic-coatings/)

Our news journalists report that additional information may be obtained by contacting A. Romo-Uribe, Johnson & Johnson Vis Care Inc, Adv Sci & Technol Div, Jacksonville, FL, United States. Additional authors for this research include K. Santiago-Santiago, G. Zavala-Padilla, A. Reyes-Mayer, M. Calixto-Rodriguez, J.A. Arcos-Casarrubias and J. Baghdachi.

Keywords for this news article include: Jacksonville, Florida, United States, North and Central America, Emerging Technologies, Inorganic Chemicals, Aluminum Silicates, Silicon Compounds, Oxygen Compounds, Silicon Dioxide, Nanotechnology, Acyclic Acids, Nanocomposite, Silicic Acid, Acrylates, Bentonite, Minerals, Oxides, Johnson & Johnson.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
12/08 JOHNSON & JOHNSON : Recent Findings from Johnson & Johnson Provides New Insights..
12/08 JOHNSON & JOHNSON : New Findings from Johnson & Johnson in Dermatology Drugs Pro..
12/08 JOHNSON & JOHNSON : Talcum Powder Lawsuits Move Forward, as California Litigatio..
12/08 Sanofi mulls counterbid for Actelion amid J&J talks
12/08DJU.S. Stocks Climb, Extending Rally
12/07 JOHNSON & JOHNSON : The Woodrow Wilson Center (WWC) - Discussion
12/07DJMARKET SNAPSHOT : Dow, S&P 500 Set Intraday Records, But Health-care Slumps On T..
12/07DJMARKET SNAPSHOT : Dow, S&P 500 On Track For Records, But Health-care Slumps On T..
12/05 Une offre de Novartis sur Actelion jugée peu probable
More news
Sector news : Pharmaceuticals - NEC
02:05pDJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04:20a DANAHER : Continued Growth Expected As M&A Activity Continues
12/08 New Oral Psoriasis Drug Tops Cellceutix Catalysts
12/08 A Quick Guide To Retiring Early
12/08 Dividend Champion Portfolio - December Update
12/08 Should Geron Opt-In?
Financials ($)
Sales 2016 72 061 M
EBIT 2016 22 017 M
Net income 2016 16 371 M
Finance 2016 18 064 M
Yield 2016 2,83%
P/E ratio 2016 18,78
P/E ratio 2017 16,55
EV / Sales 2016 3,94x
EV / Sales 2017 3,66x
Capitalization 301 952 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.05%301 952
ROCHE HOLDING LTD.-19.97%189 184
PFIZER INC.-3.38%187 755
NOVARTIS AG-20.79%178 671
MERCK & CO., INC.13.82%165 759
SANOFI-4.45%102 757
More Results